Wegovy Tablets Vs Injections

If you have been struggling with your weight for years, trying diet after diet with little lasting success, you are far from alone — and in 2026, there is now more clinical evidence than ever that a new generation of weight loss treatments can genuinely change lives. Wegovy tablets represent one of the most talked-about developments in obesity medicine, offering people a convenient, evidence-backed option that works alongside lifestyle changes to deliver meaningful, sustained results.

Quick Summary

Wegovy is a once-weekly semaglutide injection licensed in the UK for weight management in adults with obesity or overweight and at least one weight-related health condition. It works by mimicking a natural gut hormone to reduce hunger and slow digestion, helping people eat less and lose weight more sustainably than lifestyle changes alone.

• Wegovy contains semaglutide 2.4 mg and belongs to the GLP-1 receptor agonist class of medicines
• Clinical trials show average weight loss of 15–17% of body weight over 68 weeks
• Treatment starts at 0.25 mg weekly and escalates gradually over 16–20 weeks
• Common side effects include nausea, vomiting, and constipation — most settle within the first few weeks
• Available in the UK via private prescription and, in some cases, through NHS specialist weight management services

Table of Contents

1. What Is Wegovy and How Does It Work?
2. Wegovy Dosing Schedule Explained Step by Step
3. Who Can Take Wegovy in the UK?
4. Side Effects of Wegovy Tablets and How to Manage Them
5. Wegovy Tablets vs Other Weight Loss Treatments
6. How to Get Wegovy Safely in the UK
7. Key Takeaways
8. When to Seek Professional Advice
9. Scientific References
10. Frequently Asked Questions

What Is Wegovy and How Does It Work?

Wegovy is the brand name for semaglutide 2.4 mg, a once-weekly subcutaneous injection licensed in the UK for chronic weight management. It was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and has been available through UK healthcare services since 2023. Unlike older weight loss drugs that often carried significant safety concerns, Wegovy belongs to the GLP-1 receptor agonist class — a group of medicines originally developed to treat type 2 diabetes that were found to have remarkable effects on body weight.

GLP-1 stands for glucagon-like peptide-1, a hormone naturally released by your gut after you eat. It signals to your brain that you are full, slows the rate at which food leaves your stomach, and reduces the drive to eat. Wegovy mimics this hormone at a much higher dose than the diabetic version of semaglutide (Ozempic), which explains why the weight loss results are so much more dramatic. When people take Wegovy tablets — technically an injection rather than an oral tablet, though an oral semaglutide formulation is in development — they simply feel less hungry throughout the day, eat smaller portions naturally, and begin to lose weight steadily over months.

The landmark STEP 1 clinical trial, published in the New England Journal of Medicine, demonstrated that participants using semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks compared with 2.4% in the placebo group. For a person weighing 100 kg, that translates to almost 15 kg of genuine, sustained weight loss — a result previously only achievable through bariatric surgery. This level of evidence is why Wegovy has genuinely transformed the obesity treatment landscape in the UK.

• Semaglutide mimics the natural GLP-1 gut hormone to reduce hunger signals in the brain
• It slows gastric emptying, meaning you feel fuller for longer after eating
• Average weight loss in trials: 14.9–17% of body weight over 68 weeks
• MHRA-approved and supported by NICE guidance for use in eligible UK adults
• Works best when combined with a reduced-calorie diet and increased physical activity

Wegovy Dosing Schedule Explained Step by Step

One of the most common questions people have when starting treatment is how the dosing actually works — and why it takes several months to reach the full dose. The gradual dose escalation is not about being cautious for its own sake; it is genuinely important for tolerability. Starting at a high dose would almost certainly cause significant nausea and gastrointestinal discomfort that would lead many people to stop treatment before they had a chance to experience the benefits.

The standard Wegovy dosing schedule begins at 0.25 mg once weekly for the first four weeks. This is a sub-therapeutic dose — it is not producing meaningful weight loss at this stage; its only purpose is to allow your body to adjust to the medication. After four weeks, the dose increases to 0.5 mg for another four weeks, then to 1 mg, then to 1.7 mg, and finally to the full maintenance dose of 2.4 mg. This escalation process typically takes 16 to 20 weeks in total. Most people begin to notice appetite suppression from the very first weeks, with more significant weight loss becoming apparent from around weeks eight to twelve.

It is worth noting that if you experience troublesome side effects at any dose step, your prescriber may advise staying on the lower dose for an additional four weeks before escalating again. This flexibility is built into the treatment protocol because individual responses vary considerably. Some people tolerate the full escalation very smoothly; others need a little more time at intermediate doses. Neither approach is better or worse — the goal is always to reach the maintenance dose in a way that you can sustain.

• Weeks 1–4: 0.25 mg once weekly (tolerability dose, not therapeutic)
• Weeks 5–8: 0.5 mg once weekly
• Weeks 9–12: 1.0 mg once weekly
• Weeks 13–16: 1.7 mg once weekly
• Week 17 onwards: 2.4 mg once weekly (maintenance dose)
• If side effects occur, dose escalation can be paused for an extra 4 weeks

Dose Step	Weekly Dose	Duration	Primary Purpose	Expected Weight Loss
Step 1	0.25 mg	4 weeks	Tolerability/adjustment	Minimal (adjustment phase)
Step 2	0.5 mg	4 weeks	Begin appetite suppression	Early reduction in hunger
Step 3	1.0 mg	4 weeks	Increasing therapeutic effect	Noticeable weight reduction begins
Step 4	1.7 mg	4 weeks	Near-therapeutic effect	Significant weight loss ongoing
Step 5 (Maintenance)	2.4 mg	Ongoing	Full therapeutic maintenance	Average 14.9–17% body weight loss by week 68

Who Can Take Wegovy in the UK?

Not everyone who wants to lose weight is eligible for Wegovy, and understanding the criteria can save you a great deal of confusion when you approach a prescriber. NICE guidance, updated in 2026, outlines that Wegovy is indicated for adults with a body mass index (BMI) of 30 kg/m² or above (classified as obese), or adults with a BMI of 27 kg/m² or above who also have at least one weight-related health condition such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease.

Wegovy is not suitable for everyone. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma, or in those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should not be used in pregnancy or during breastfeeding, and women of childbearing age are advised to use effective contraception during treatment and for at least two months after stopping. People with a history of pancreatitis should discuss the risks carefully with their prescriber before starting. Anyone with severe kidney or liver disease should also have their eligibility assessed individually.

It is also important to understand that Wegovy is a long-term treatment, not a quick fix. NICE guidance is clear that weight management medicines work best as part of a comprehensive programme that includes dietary advice, physical activity support, and behavioural intervention. If you stop Wegovy without having made underlying lifestyle changes, there is a well-documented tendency for weight to be regained over time. This is not a failure of the drug — it reflects the chronic nature of obesity as a condition rather than a simple lack of willpower.

• BMI ≥ 30 kg/m² — eligible on weight criteria alone
• BMI ≥ 27 kg/m² with a weight-related condition — eligible with comorbidities
• Not suitable during pregnancy, breastfeeding, or with a personal/family history of MEN 2
• History of pancreatitis requires individual risk assessment with a prescriber
• Must be used alongside dietary and lifestyle support for best long-term outcomes

Side Effects of Wegovy Tablets and How to Manage Them

Side effects are one of the biggest concerns people have before starting any new medication, and it is completely reasonable to want to know what to expect. The most commonly reported side effects with Wegovy are gastrointestinal in nature — nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These tend to be most noticeable during the dose escalation phase, particularly when moving from one dose step to the next. For the majority of people, these symptoms settle significantly once the body has adapted to each new dose level.

Practical strategies to minimise gastrointestinal side effects include eating smaller meals, avoiding high-fat or spicy foods during the adjustment period, and injecting Wegovy at a consistent time each week. Some people find that injecting in the evening means any nausea occurs during sleep, reducing its impact on daily life. Staying well hydrated is also important, particularly if you experience any vomiting or diarrhoea. If nausea is persistent and significantly affecting your quality of life, speak to your prescriber — there are safe antiemetic medicines that can help in the short term while you adjust.

Less common but more serious side effects to be aware of include pancreatitis (inflammation of the pancreas), which should be suspected if you develop severe persistent abdominal pain that radiates to the back. Gallbladder problems, including gallstones, have also been reported with GLP-1 medicines, likely because rapid weight loss increases the risk of gallstone formation regardless of the treatment used. There have been reports of a rare but serious condition called non-arteritic anterior ischaemic optic neuropathy (NAION) in people using semaglutide, though a direct causal link has not been conclusively established. As always, if you experience any sudden changes in vision, you should seek urgent medical attention.

• Nausea: most common, typically settles within 4–8 weeks at each dose step
• Vomiting and diarrhoea: manageable with dietary adjustments and hydration
• Constipation: increase fibre and fluid intake; over-the-counter support is available
• Injection site reactions: mild redness or bruising, usually resolve quickly
• Serious but rare: pancreatitis, gallbladder disease, changes in heart rate — report immediately
• Fatigue and headache: often transient during early treatment weeks

Wegovy Tablets vs Other Weight Loss Treatments

With a growing number of weight loss treatments available in the UK, it can be genuinely difficult to know which option is right for you. Wegovy is often compared most directly to Mounjaro weight loss injections (tirzepatide), which works on both GLP-1 and GIP receptors and has shown average weight loss of up to 20–22% in the SURMOUNT trials. Both are once-weekly injections, but Mounjaro is a dual-agonist and may be more effective for some individuals — though individual responses always vary considerably.

Older GLP-1 treatments such as Saxenda (liraglutide 3 mg) are daily injections rather than weekly, which many people find less convenient. Clinical trials show Saxenda produces average weight loss of around 8–9% compared to Wegovy's 15–17%, making Wegovy the more effective option based on head-to-head evidence. At the other end of the spectrum, over-the-counter options such as Orlos (orlistat) 60mg weight loss aid work by blocking fat absorption in the gut rather than reducing appetite. Orlistat can be helpful for some people but tends to produce more modest weight loss of around 5–7% and can cause significant gastrointestinal side effects if a high-fat diet is consumed.

Purely lifestyle-based supplements such as XLS Medical Weight Loss Plus tablets or XLS Medical Direct Fat Binder sachets can support weight management as part of a balanced diet but are unlikely to deliver the scale of weight loss seen with prescription GLP-1 treatments. Choosing between options should always be guided by a prescriber who can assess your BMI, medical history, and personal preferences.

• Wegovy (semaglutide 2.4 mg): weekly injection, average 15–17% weight loss, MHRA approved
• Mounjaro (tirzepatide): weekly injection, dual GLP-1/GIP agonist, up to 20–22% weight loss in trials
• Saxenda (liraglutide 3 mg): daily injection, average 8–9% weight loss, less convenient
• Orlistat (Orlos): oral capsule, fat absorption blocker, modest 5–7% weight loss
• OTC supplements: supportive role only, not clinically comparable to prescription treatments

How to Get Wegovy Safely in the UK

Getting access to Wegovy in the UK requires a valid prescription from a qualified healthcare professional — it cannot be purchased over the counter. In 2026, there are two main routes: through an NHS specialist weight management service, or via a private online prescriber. NHS access remains limited and is typically reserved for people with the highest clinical need, often those with a BMI above 35 and significant comorbidities referred to a tier 3 or tier 4 weight management service. Waiting lists can be long, and not all areas have equal provision, which reflects the ongoing postcode lottery in NHS obesity services.

Private online prescribing has made access far more practical for many people. Reputable UK-registered online pharmacies and prescribing services allow you to complete a medical questionnaire, which is reviewed by a GPhC-registered pharmacist prescriber or a GMC-registered doctor. If you meet the clinical criteria, a prescription is issued and your medication is dispatched discreetly to your home. It is critically important to only use services registered with the CQC (Care Quality Commission) and GPhC, and that the prescribers reviewing your case are genuinely qualified — not simply passing through applications automatically.

When you receive your Wegovy pens, store them in the refrigerator at 2–8°C until the day of your injection. Once removed from the fridge, a pen can be kept at room temperature (below 30°C) for up to 28 days. Inject into the fatty tissue of your abdomen, thigh, or upper arm, rotating sites weekly to avoid localised reactions. Never inject into a vein or muscle. If you miss a dose, inject as soon as you remember — but if it is within two days of your next scheduled dose, skip the missed one and continue as normal.

• Wegovy requires a prescription from a CQC-registered or GMC/GPhC-qualified UK prescriber
• NHS access is limited — most patients access Wegovy through private prescribing services
• Store pens in the fridge (2–8°C); once opened, use within 28 days at room temperature
• Inject subcutaneously into the abdomen, thigh, or upper arm — rotate sites weekly
• Only ever use services registered with the GPhC and CQC for safe, legitimate prescribing
• Regular follow-up appointments every 3–6 months are recommended to monitor progress

Key Takeaways

• Wegovy (semaglutide 2.4 mg) is a once-weekly GLP-1 receptor agonist licensed in the UK for weight management in adults with obesity or overweight with comorbidities
• Clinical trial data shows average weight loss of 14.9–17% of body weight over 68 weeks — the most significant results seen with any licensed weight loss medicine in the UK
• The dose escalation schedule is carefully designed for tolerability, starting at 0.25 mg and reaching 2.4 mg over 16–20 weeks
• Most side effects are gastrointestinal and temporary; serious adverse effects are rare but require prompt medical attention if suspected
• Wegovy works best as part of a structured programme including dietary and lifestyle support, and should only be prescribed by a qualified UK-registered healthcare professional

When to Seek Professional Advice

While Wegovy is a well-tolerated treatment for the majority of people, there are circumstances where you should contact your prescriber or seek urgent medical attention without delay. If you experience severe and persistent abdominal pain — particularly pain that radiates to the back — stop taking Wegovy and seek urgent care, as this could indicate pancreatitis. Similarly, any sudden changes in vision, yellowing of the skin or eyes (which may suggest gallbladder or liver issues), or an unusually fast resting heart rate warrant an immediate medical review.

You should also speak to your prescriber if you are not losing weight after 12–16 weeks at the maintenance dose of 2.4 mg, as this may indicate that an alternative treatment would be more appropriate for you. If you develop signs of a severe allergic reaction — swelling of the face, lips, tongue or throat, difficulty breathing, or a widespread rash — call 999 immediately. For people with diabetes who are also taking insulin or sulfonylureas, close blood glucose monitoring is essential when starting Wegovy, as dose adjustments to diabetes medication may be required to avoid hypoglycaemia.

Regular check-ins with your prescriber are not merely a formality — they are a genuine opportunity to assess your progress, manage any side effects proactively, and ensure the treatment continues to be right for you as your health evolves. If you are unsure whether Wegovy is still working effectively for you, or if you have any concerns about your treatment at any point, do not hesitate to reach out to your healthcare provider.

Scientific References

1. Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989–1002. (STEP 1 Trial)
2. National Institute for Health and Care Excellence (NICE). (2023). Semaglutide for managing overweight and obesity. Technology Appraisal Guidance TA875.
3. Lincoff AM et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial). New England Journal of Medicine, 389, 2221–2232.

Frequently Asked Questions

How long does it take for Wegovy tablets to work?

Wegovy tablets typically begin suppressing appetite within the first one to two weeks of starting treatment, but meaningful weight loss — usually around 5% of body weight — is most noticeable from weeks eight to twelve onwards as the dose is gradually increased to the maintenance level of 2.4 mg weekly.

Is Wegovy safe to use long term?

Wegovy is considered safe for long-term use based on clinical trial data spanning over two years; the SELECT trial published in 2023 confirmed cardiovascular safety benefits. However, it should only be continued under regular medical supervision, with ongoing monitoring of weight, blood pressure, and any side effects that develop over time.

Can you take Wegovy with other weight loss medications?

Wegovy should not be combined with other GLP-1 receptor agonists or injectable weight loss medicines such as Saxenda or Wegovy tablets alternatives. It may be used alongside some over-the-counter weight management supplements, but this must always be discussed with a prescriber first to avoid interactions or duplication of effect.

What is the starting dose of Wegovy tablets?

The starting dose of Wegovy is 0.25 mg once weekly for the first four weeks, which is a sub-therapeutic dose designed to improve tolerability. The dose is then escalated every four weeks through 0.5 mg, 1 mg, 1.7 mg, and finally to the maintenance dose of 2.4 mg once weekly over approximately sixteen to twenty weeks.